Moderna And The All-American Drug Pricing Hearing
Executive Summary
Moderna’s time in the hot seat of the US drug pricing debate went about as well as it could for the company. The firm astutely set a tone of an All-American success story – but the hearing also showcased other ‘only in America’ themes.
You may also be interested in...
HHS Officials Raise Concerns About Pricing, Patent Restrictions for Medical Countermeasures
US FDA Commissioner and Health and Human Services Assistant Secretary for Preparedness and Response cautioned against changes to rewards for medical countermeasure developers in the next Pandemic and All-Hazards Preparedness Act reauthorization that might discourage biotech companies from working with the government.
Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders
Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.
COVID Vaccine Transition Planning: Price Does Not Come Up At ACIP
US CDC is starting to prepare for the transition of COVID vaccine deliver to more traditional commercial channels. It is noteworthy that the first discussion of what will change did not include any talk of prices.